Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.

Trends in cancer - 1 Jan 2021

Adashek Jacob J, Subbiah Vivek, Kurzrock Razelle

Abstract excerpt

Precision medicine has exploited next-generation sequencing (NGS) and gene/immune-targeted drug deployment to transform the outlook for several lethal cancers. For instance, there are now several FDA-approved medications that target the sequelae of aberrant genes in a tissue-agnostic approach: pembrolizumab [microsatellite instability and tumor mutational burden (TMB) ≥10 mutations/megabase (mut/Mb)] and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Data Mining
Share to Datasets as Topic
Share to Drug Approval

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Heterogeneity

Share to Medical Oncology

Share to Microsatellite Instability

Share to Molecular Targeted Therapy

Share to United States Food and Drug Administration

Source

Identifiers

PMID: 33008795
DOI: 10.1016/j.trecan.2020.08.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.PMID 33008795Read ↗

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right GenomicsSemantic proximity Read ↗

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.Semantic proximity Read ↗

The Future of Precision Oncology.Semantic proximity Read ↗

Tissue-Agnostic Drug Development: A New Path to Drug ApprovalSemantic proximity Read ↗

Advances in Personalized OncologySemantic proximity Read ↗

Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug DevelopmentSemantic proximity Read ↗

Precision Oncology: Who, How, What, When, and When Not?Semantic proximity Read ↗

Precision oncology based on omics data: The NCT Heidelberg experienceSemantic proximity Read ↗

If it's a target, it's a pan-cancer target: Tissue is not the issue.Semantic proximity Read ↗

The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signalling Pathways Is a Means to an EndSemantic proximity Read ↗

Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.Semantic proximity Read ↗

Novel clinical trial designs emerging from the molecular reclassification of cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.